Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Hims & Hers Health (HIMS)

Hims & Hers enters $400 million receivables sale facility with JPMorgan Chase

Neutral Impact 3 of 5 financing Written later

Hims & Hers subsidiaries XeCare LLC and Apostrophe Pharmacy LLC entered a Master Receivables Purchase Agreement with JPMorgan Chase Bank on July 1, 2026, allowing them to sell eligible receivables for cash, subject to a $400 million facility limit. The company also agreed to guarantee the sellers' performance under the agreement, though not the collectability of the receivables, and amended its credit agreement to permit the arrangement.

Key points

  • Facility limit for eligible receivables is $400 million, with an initial term of 364 days that may be extended.
  • The company guarantees the sellers' performance under the agreement but not receivable collectability or seller creditworthiness.
  • Amendment No. 4 to the Revolving Credit and Guaranty Agreement, dated June 26, 2026, adds a $400 million debt basket for this arrangement.
  • The filing does not disclose the purchase discount or any financial results tied to the arrangement.

The filing

CompanyHims & Hers Health (HIMS)
Form8-K, current report
Filed with the SECJul 1, 2026, 5:02 PM ET
Accession number0001773751-26-000146

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.